Journal of Neuro-Oncology

, Volume 101, Issue 3, pp 345–355

High-dose chemotherapy with hematopoietic stem cell transplantation for the treatment of primary central nervous system lymphoma

  • Christopher J. Campen
  • Rebecca L. Tombleson
  • Myke R. Green
Topic Review

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare B-cell lymphoid neoplasm for which current regimens utilizing standard-dose chemotherapy and/or radiation therapy lead to high relapse rates and/or unacceptable neurologic sequelae. High-dose chemotherapy followed by hematopoietic stem cell transplantation may overcome limitations of current treatment schemas. A search was performed of all English-language literature (1968 to June 2009) within the MEDLINE, EMBASE and Cochrane Library databases to identify relevant clinical trials using the terms stem cell transplantation, bone marrow transplantation, primary central nervous system lymphoma, and PCNSL. Bibliographies were reviewed to extract other relevant articles. Use of high-dose chemotherapy followed by hematopoietic stem cell transplantation for the treatment of PCNSL in a predominantly elderly population is feasible. Use of this treatment modality for newly diagnosed and recurrent or relapsed disease is burdened by a paucity of data guiding patient selection, optimal induction regimen, stem cell mobilization and conditioning chemotherapy. Data are also sparse and confounding regarding timing of initiation of this procedure relative to the natural history of the disease and timing of each chemotherapy regimen relative to each other. High-dose chemotherapy followed by hematopoietic stem cell transplantation remains an experimental procedure with insufficient data to guide clinicians. However, the data are encouraging and merit continued research to guide patient selection and treatment regimens which may produce optimal outcomes.

Keywords

Stem cell transplantation Dose intensity Primary CNS lymphoma PCNSL High dose chemotherapy 

References

  1. 1.
    Schabet M (1999) Epidemiology of primary CNS lymphoma. J Neuro-Oncol 43:199–201CrossRefGoogle Scholar
  2. 2.
    DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93–10. J Clin Oncol 20:4643–4648CrossRefPubMedGoogle Scholar
  3. 3.
    Ferreri AJM, Reni M, Foppoli M et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374:1512–1520CrossRefPubMedGoogle Scholar
  4. 4.
    Plotkin SR, Batchelor TT (2001) Primary nervous-system lymphoma. Lancet Oncol 2:354–365CrossRefPubMedGoogle Scholar
  5. 5.
    Bhagavathi S, Wilson J (2008) Primary central nervous system lymphoma. Arch Pathol Lab Med 132:1830–1834PubMedGoogle Scholar
  6. 6.
    Ferrari AJM, Blay JY, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol 21:266–272CrossRefGoogle Scholar
  7. 7.
    Abrey L, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the memorial sloan-kettering cancer center prognostic model. J Clin Oncol 24:5711–5715CrossRefPubMedGoogle Scholar
  8. 8.
    Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570–4574CrossRefPubMedGoogle Scholar
  9. 9.
    Green MR, Chowdhary S, Lombardi KM, Chalmers LM, Chamberlain M (2006) Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma. Expert Rev Neurother 6:635–652CrossRefPubMedGoogle Scholar
  10. 10.
    Nguyen PL, Chakravarti A, Finkelstein DM et al (2005) Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23:1507–1513CrossRefPubMedGoogle Scholar
  11. 11.
    Plotkin SR, Betensky RA, Hochberg FH et al (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10:5643–5646CrossRefPubMedGoogle Scholar
  12. 12.
    Reni M, Ferreri AJM, Landoni C, Villa E (2000) Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 92:575–576CrossRefPubMedGoogle Scholar
  13. 13.
    Reni M, Mason W, Zaja F et al (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40:1682–1688CrossRefPubMedGoogle Scholar
  14. 14.
    Reni M, Zaja F, Mason W et al (2007) Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 96:864–867CrossRefPubMedGoogle Scholar
  15. 15.
    Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901–903PubMedGoogle Scholar
  16. 16.
    Wong ET, Tishler R, Barron L, Wu J (2004) Immunochemotherapy with rituximab and temozolomide for PCNSL. Cancer 101:139–145CrossRefPubMedGoogle Scholar
  17. 17.
    Pitini V, Baldari S, Altavilla G, Arrigo C, Naro C, Perniciaro F (2007) Salvage therapy for primary central nervous system lymphoma with 90Y-ibritumomab and temozolomide. J Neurooncol 83:291–293CrossRefPubMedGoogle Scholar
  18. 18.
    Fischer L, Thiel E, Klasen HA, Kirchen H, Jahnke K, Korfel A (2004) Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan. Neurology 62:1885–1887PubMedGoogle Scholar
  19. 19.
    Fischer L, Thiel E, Klasen HA et al (2006) Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 17:1141–1145CrossRefPubMedGoogle Scholar
  20. 20.
    Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T (2008) Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neuro-Oncol 86:211–215CrossRefGoogle Scholar
  21. 21.
    Arellano-Ridrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F (2003) Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma. Eur J Haematol 70:219–224CrossRefGoogle Scholar
  22. 22.
    Yamanaka R, Homma J, Sano M et al (2007) Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study. Leuk Lymphoma 48:1429–1433CrossRefPubMedGoogle Scholar
  23. 23.
    Herrlinger U, Brugger W, Bamberg M, Küker W, Dichgans J, Weller M (2000) PCV salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 54(8):1707–1708PubMedGoogle Scholar
  24. 24.
    Goldspiel B (2004) Chemotherapy dose density in early-stage breast cancer and non-Hodgkin’s lymphoma. Pharmacotherapy 24:1347–1357CrossRefPubMedGoogle Scholar
  25. 25.
    Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree structured survival analysis. J Clin Oncol 8:963–977PubMedGoogle Scholar
  26. 26.
    Epelbaum R, Faraggi D, Ben-Arie Y et al (1990) Survival of diffuse large cell lymphoma. A multi-variate analysis including dose intensity variables. Cancer 66:1124–1129CrossRefPubMedGoogle Scholar
  27. 27.
    Tilly H, Lepage E, Coiffier B et al (2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102:4284–4289CrossRefPubMedGoogle Scholar
  28. 28.
    Pfreundschuh M, Trumper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626–633CrossRefPubMedGoogle Scholar
  29. 29.
    Pfreundschuh M, Trumper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634–641CrossRefPubMedGoogle Scholar
  30. 30.
    Holmberg LA, Stewart FM (2006) Revisiting the role of dose intensity in hematological malignancies. Exp Hematol 34:811–825CrossRefPubMedGoogle Scholar
  31. 31.
    Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545CrossRefPubMedGoogle Scholar
  32. 32.
    Milpied N, Deconinck E, Gaillard F et al (2004) Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350:1287–1295CrossRefPubMedGoogle Scholar
  33. 33.
    Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T, Fukushima T (2003) Long term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy. J Neuro-Oncol 63:87–95CrossRefGoogle Scholar
  34. 34.
    Illerhaus G, Marks R, Müller F et al (2009) High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 20:319–325CrossRefPubMedGoogle Scholar
  35. 35.
    Joerger M, Huitema ADR, Krähenbühl S et al (2010) Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 102:673–677CrossRefPubMedGoogle Scholar
  36. 36.
    Ferreri AJ, Guerra E, Regazzi M et al (2004) Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 90:353–358CrossRefPubMedGoogle Scholar
  37. 37.
    de Boer AG, Gaillard PJ (2007) Drug targeting to the brain. Ann Rev Pharmacol Toxicol 47:325–355Google Scholar
  38. 38.
    Muldoon LL, Soussain C, Jahnke K et al (2007) Chemotherapy delivery issues in central nervous system malignancies: a reality check. J Clin Oncol 25:2295–2305CrossRefPubMedGoogle Scholar
  39. 39.
    Fliessbach K, Helmstaedter C, Urbach H et al (2005) Neuropsychological outcome after chemotherapy for primary CNS lymphoma. Neurology 64:1184–1188PubMedGoogle Scholar
  40. 40.
    Herrlinger U, Schabet M, Bitzer D, Petersen D, Krauseneck P (1999) Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol 43:219–226CrossRefPubMedGoogle Scholar
  41. 41.
    Crossen JR, Garwood D, Glatstein E, Neuwelt EA (1994) Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12:627–642PubMedGoogle Scholar
  42. 42.
    Armstrong CL, Hunter JV, Ledakis GE et al (2002) Late cognitive and radiographic changes related to radiotherapy. Neurology 59:40–48PubMedGoogle Scholar
  43. 43.
    DeAngelis LM, Shapiro WR (1991) Drug/radiation interactions and central nervous system injury. In: Gutin PH, Leibel SA, Sheline GE (eds) Radiation injury to the central nervous system. Raven Press, New York, pp 361–382Google Scholar
  44. 44.
    Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548–555PubMedGoogle Scholar
  45. 45.
    Omuro AMP, Ben-Porat LS, Panageas KS et al (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62:1595–1600CrossRefPubMedGoogle Scholar
  46. 46.
    Ferreri AJ, Reni M (2007) Primary central nervous system lymphoma. Crit Rev Oncol Hematol 63:257–268CrossRefPubMedGoogle Scholar
  47. 47.
    Ferreri AJ, Abrey LE, Blay JY et al (2003) Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 21:2407–2414CrossRefPubMedGoogle Scholar
  48. 48.
    Blay JY, Conroy T, Chevreau C et al (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16:864–871PubMedGoogle Scholar
  49. 49.
    Reni M, Ferreri AJ, Garancini MP, Villa E (1997) Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 8:227–234CrossRefPubMedGoogle Scholar
  50. 50.
    Batchelor T, Carson K, O’Neill A et al (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07. J Clin Oncol 21:1044–1049CrossRefPubMedGoogle Scholar
  51. 51.
    Mehnert A, Scherwath A, Schimer L et al (2007) The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 66:108–118CrossRefPubMedGoogle Scholar
  52. 52.
    Khalfallah S, Stamatoullas A, Fruchart C, Proust F, Delangre T, Tilly H (1996) Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transpl 18:1021–1023Google Scholar
  53. 53.
    Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24:1281–1288CrossRefPubMedGoogle Scholar
  54. 54.
    Soussain C, Suzan F, Hoang-Xuan K et al (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19:742–749PubMedGoogle Scholar
  55. 55.
    Soussain C, Hoang-Xuan K, Taillandier L et al (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 26:2512–2518CrossRefPubMedGoogle Scholar
  56. 56.
    Patte C, Leverger G, Perel Y et al (1990) Updated results of the LMB86 protocol of the French Pediatric Oncology Society (SFOP) for B-cell non-hodgkin’s lymphoma (B-NHL) with CNS involvement (CNS+) and B-ALL. Med Pediatr Oncol 18:406 (abstr)Google Scholar
  57. 57.
    Gerstner E, Batchelor T (2007) Primary CNS lymphoma. Expert Rev Anticanc Ther 7:689–700CrossRefGoogle Scholar
  58. 58.
    Abrey LE, Moskowitz CH, Mason WP et al (2001) A phase II study of intensive methotrexate and cytarabine followed by high dose BEAM chemotherapy with autologous stem cell transplantation (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL). Proc Am Soc Clin Oncol 20:A2055 (abstr 207)Google Scholar
  59. 59.
    Abrey LE, Moskowitz CH, Mason WP et al (2003) Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21:4151–4156CrossRefPubMedGoogle Scholar
  60. 60.
    Ferreri AJ, Crocchiolo R, Assanelli A, Govi S, Reni M (2008) High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk Lymphoma 49:2042–2047CrossRefPubMedGoogle Scholar
  61. 61.
    Wiebe VJ, Smith BR, Degregorio MW, Rappeport JM (1992) Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol 13:241–270CrossRefPubMedGoogle Scholar
  62. 62.
    Holthus JM, Postmus PE, Van Oort WJ et al (1986) Pharmacokinetics of high-dose etoposide (VP16–213). Eur J Cancer Clin Oncol 22:1149–1155CrossRefGoogle Scholar
  63. 63.
    Gouyette A, Hartmann O, Pico JL (1986) Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 16:184–189CrossRefPubMedGoogle Scholar
  64. 64.
    Ho DHW, Frei E III (1971) Clinical pharmacology of 1-B-D-ara-binofuranosyl cytosine. Clin Pharmacol 12:944–954Google Scholar
  65. 65.
    Breithaupt H, Pralle H, Eckhardt T, von Hattingberg M, Schick J, Löffler H (1982) Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C). Cancer 50:1248–1257CrossRefPubMedGoogle Scholar
  66. 66.
    Cheng T, Forsyth P, Chaudhry A et al (2003) High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transpl 31:679–685CrossRefGoogle Scholar
  67. 67.
    Brevet M, Garidi R, Gruson B, Royer B, Vaida I, Damaj G (2005) First-line autologous stem cell transplantation in primary CNS lymphoma. Eur J Haematol 75:288–292CrossRefPubMedGoogle Scholar
  68. 68.
    Colombat P, Lemevel A, Bertrand P et al (2006) High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transpl 38:417–420CrossRefGoogle Scholar
  69. 69.
    Illerhaus G, Marks R, Ihorst G et al (2006) High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24:3865–3870CrossRefPubMedGoogle Scholar
  70. 70.
    Illerhaus G, Müller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J (2008) High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 93:147–148CrossRefPubMedGoogle Scholar
  71. 71.
    Montemurro M, Kiefer T, Schüler F et al (2007) Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hämato-Onkologie OSHO-53 phase II study. Ann Oncol 18:665–671CrossRefPubMedGoogle Scholar
  72. 72.
    Varadi G, Or R, Kapelushnik J et al (1999) Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma. Leuk Lymphoma 34:185–190PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Christopher J. Campen
    • 1
    • 2
  • Rebecca L. Tombleson
    • 3
  • Myke R. Green
    • 1
    • 2
  1. 1.Department of PharmacyUniversity Medical CenterTucsonUSA
  2. 2.Department of Hematology and Medical OncologyArizona Cancer Center/University Medical CenterTucsonUSA
  3. 3.Department of Oncological SciencesH. Lee Moffitt Cancer Center and Research InstituteTampaUSA

Personalised recommendations